Humanized monoclonal antibodies in the regulation of atypical manifestations of upper respiratory tract inflammation

One of the urgent issues for otorhinolaryngologists and doctors of related specialties is the early diagnosis of atypical manifestations of upper respiratory tract inflammation, the study of etiopathogenetic mechanisms of the disease, the provision of highly qualified medical care and the adoption of effective preventive measures. In this context, chronic idiopathic urticaria in people suffering from allergic rhinitis with and without nasal polyposis is the most in-demand for study. The main task of writing the article by the team of authors was to evaluate the effectiveness and substantiate the prospects of using a humanized monoclonal antibody in the treatment of allergic rhinitis with comorbid chronic idiopathic urticaria. The analysis of literary sources (articles and relevant abstracts) covering topical issues of etiopathogenetic mechanisms of development of chronic idiopathic urticaria in people suffering from allergic rhinitis, clinical features and experience in the use of humanized monoclonal antibodies has been carried out. Scientific bases have been used Elibrary.ru, Google, Yandex, Scopus, Pubmed, etc. The main pathogenetic links of allergic rhinitis and chronic urticaria are highlighted, modern data on the possibilities of conservative therapy of IgE-mediated inflammation are summarized. The results of the analysis showed that the use of a humanized monoclonal antibody in the treatment of allergic rhinitis with comorbid chronic idiopathic urticaria makes it possible to establish control over the symptoms of the disease in a short time. Clinical cases are presented illustrating the positive dynamics of manifestations of allergic rhinitis and chronic idiopathic urticaria in the form of a reduction in skin rashes and nasal rhinological symptoms as early as day 14 of therapy, complete relief of symptoms during 3 months of treatment with Omalizumab in the form of a ready-made solution, confirmed by a persistent tendency to normalize the level of total IgE from the initial 389 to 136 IU/ml for 1.5 months, followed by a decrease to 98.4 IU/ml by 3 months of biological therapy.

1. Горохов АА, Янов ЮК, Дворянчиков ВВ, Миронов ВГ. Оториноларингология. Санкт-Петербург: СпецЛит; 2019. 224 с. Режим доступа: https://www.trauma-books.ru/otorino_gorohov.pdf.

2. Янова ЮК, Крюкова АИ, Дворянчикова ВВ, Носули ЕВ и др. Оториноларингология: национальное руководство. М.: ГЭОТАР-Медиа; 2024. 992 с. https://doi.org/10.33029/9704-8213-1-ORL-2024-1-992.

3. Ryazantsev SV, Krivopalov AA, Eremin SA, Shamkina PA. Topical antibacterial therapy in the inflammatory diseases treatment of the nasal cavity, paranasal sinuses, and complications prevention. RMJ. 2019;(8-1):55–59. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Topicheskaya_antibakterialynaya_terapiya_v_lechenii_vospalitelynyh_zabolevaniy_polosti_nosa_okolonosovyh_pazuh_i_profilaktike_osloghneniy.

4. Kryukov EV, Zhdanov KV, Kozlov KV, Kravtsov VYu, Mal’tsev OV, Sukachev VS et al. Electron microscopic changes in the nasal membrane of patients with COVID-19 depending on the clinical form and the period of the disease. Jurnal Infektologii. 2021;13(2):5–13. (In Russ.) https://doi.org/10.22625/2072-6732-2021-13-2-5-13.

5. Jia HX, He YL. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Ther. 2020;27(5):e455–e467. https://doi.org/10.1097/MJT.0000000000000912.

6. orkmazov MYu, Lengina MA, Korkmasov AM, Kravchenko AYu. Effect of post-COVID syndrome on the quality of life of patients with allergic rhinitis and eosinophilic phenotype of chronic polyposis rhinosinusitis. Medical Journal of the Russian Federation. 2023;29(4):277–290. (In Russ.) https://doi.org/10.17816/medjrf472079.

7. Astafieva NG, Baranov AA, Vishneva EA, Daihes NA, Zhestkov AB, Ilina NI et al. Allergic rhinitis. Russian Journal of Allergy. 2022;19(1):100–141.(In Russ.) https://doi.org/10.36691/RJA1524.

8. Karpishchenko SA, Krivopalov AA, Eremin SA, Shamkina PA, Chufistova AV. Topical antimicrobial therapy of infectious and inflammatory diseases of the nose and paranasal sinuses. RMJ. 2020;(5):26–30. (In Russ.) Available at: https://www.rmj.ru/articles/otorinolaringologiya/Topicheskaya_antimikrobnaya_terapiya_infekcionno-vospalitelynyh_zabolevaniy_nosa_i_okolonosovyh_pazuh.

9. Berezhansky PV, Shubin LB, Chuprikova NP. Prevalence of allergic rhinitis among children living in the Odintsovo city district of the Moscow regoin. Medical and Pharmaceutical Journal “Pulse”. 2022;24(5):5–12. (In Russ.) https://doi.org/10.26787/nydha-2686-6838-2022-24-5-5-12.

10. Nenasheva NM, Nosulya EV, Kurbacheva OM, Svistushkin VM, Kim IA, Lopatin AS et al. Effectiveness of fixed combination of olopatadine hydrochloride and mometasone furoate in adults and children with allergic rhinitis in real-life clinical practice settings: results of «RYAL» prospective observational study. Russian Rhinology. 2024;32(1):16–26. (In Russ.) https://doi.org/10.17116/rosrino20243201116.

11. Wise SK, Lin SY, Toskala E. International consensus statement on allergy and rhinology: allergic rhinitis – executive summary. Int Forum Allergy Rhinol. 2018;8(2):85–107. https://doi.org/10.1002/alr.22070.

12. Pavlova SS, Korneenkov AA, Dvorianchikov VV, Ryazantsev SV, Ryazantseva ES, Donskaya OS. Assessment of population health losses due to nasal obstruction based on the concept of the global burden of disease: general approaches and research directions. Meditsinskiy Sovet. 2021;(12):138–145. (In Russ.) https://doi.org/10.21518/2079-701X-2021-12-138-145.

13. Глазников ЛА, Дворянчиков ВВ, Егоров ВИ, Сыроежкин ФА, Буйнов ЛГ, Мельник АМ. Медицинская помощь при травмах лор органов в условиях чрезвычайных ситуаций. В: Victims in Emergency Situations. Management, Trauma And PTSD, Pharmacology, Rehabilitation, Innovations. Нью-Йорк: Xlibris LLC; 2014. С. 260–320. Режим доступа: https://www.elibrary.ru/uakfbn.

14. Dvoryanchikov VV, Yanov YuK, Govorun MI. On the issue of the stage-bystage treatment of patients with chronic purulent otitis media. Journal of Ear, Nasal and Throat Diseases. 2004;(6):9–13. (In Russ.) Available at: https://www.elibrary.ru/bramzp.

15. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. https://doi.org/10/1016/j/jaci.2017.03.050.

16. Горохов АА, Янов ЮК, Шелепов АМ, Дворянчиков ВВ, Миронов ВГ. Военная оториноларингология. СПб.: Спец Лит; 2014. 271 с.

17. Gofman VV, Dvoryanchikov VV. Bacteriologic and immunologic status in patients with chronic tonsillitis current position. Russian Otorhinolaryngology. 2014;(2):19–23. (In Russ.) Available at: https://entru.org/files/j_rus_LOR_2_2014.pdf.

18. Korkmazov MYu, Lengina MA, Dubinets ID, Korkmazov AM, Smirnov AA. Opportunities for correction of individual links of the pathogenesis of allergic rhinitis and bronchial asthma with assessment of the quality of life of patients. Meditsinskiy Sovet. 2022;(4):24–34. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-4-24-34.

19. Korkmazov AM, Korkmazov MYu. Methods of correction of phagocyte functional disorders and local manifestations of oxidative stress in the nasal mucosa using ultrasonic cavitation. Russian Journal of Immunology. 2018;21(3):325–328. (In Russ.) https://doi.org/10.31857/S102872210002404-9.

20. Dvoryanchikov VV, Mironov VG, Grigoriev SG, Chernysh AV, Sergeev AN, Koroleva KYu, Sushcheva NA. Description of the modern combat acoustic trauma. Military Medical Journal. 2020;341(6):16–20. (In Russ.) Available at: https://journals.eco-vector.com/0026-9050/article/view/82241.

21. Korkmazov MYu, Lengina MA, Dubinets ID, Kravchenko AYu, Klepikov SV. Some immunological aspects of targeted therapy of polypous rhinosinusitis. Russian Journal of Immunology. 2023;26(3):301–306. (In Russ.) https://doi.org/10.46235/1028-7221-8955-SIA.

22. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, Bernstein JA et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. https://doi.org/10.1111/all.13397.

23. Кубанов АА, Баранов АА, Намазова-Баранова ЛС, Аравийская ЕР, Астафьева НГ, Базаев ВТ и др. Крапивница. Клинические рекомендации. 2023. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/264_2.

24. Korkmazov MYu, Yastremsky AP, Kornova NV, Lengina MA, Korkmazov AM. Therapeutic and diagnostic approaches in the treatment of chronic tonsillitis. Meditsinskiy Sovet. 2022;(20):90–99. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-20-90-99.

25. Krivopalov AA, Moroz NV, Belicheva EG, Lengina MA. Phage therapy in overcoming antibiotic resistance in chronic rhinosinusitis. Vestnik OtoRino-Laringologii. 2023;88(6):48–55. (In Russ.) https://doi.org/10.17116/otorino20238806148.

26. Korkmazov MYu, Angelovich MS, Lengina MA, Belousov SYu. Clinical case of angiosarcoma of ethmoidal labyrinth and frontal sinus, issues of morphological verification of diagnosis. Vestnik Oto-Rino-Laringologii. 2022;87(4):102–106. (In Russ.) https://doi.org/10.17116/otorino202287041102.

27. Korkmazov MYu, Kazachkov EL, Lengina MA, Dubinets ID, Korkmazov AM. Cause-effect factors of rhinosinusitis poliposa development. Russian Rhinology. 2023;31(2):124–130. (In Russ.) https://doi.org/10.17116/rosrino202331021124.

28. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. https://doi.org/10.1111/all.15090.

29. Caffarelli C, Paravati F, El Hachem M, Duse M, Bergamini M, Simeone G et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101. https://doi.org/10.1186/s13052-019-0695-x.

30. Geissbühler Y, Balp MM, McConnon A, Gomme J, McKenna SJ, Kohli RK, Soong W. Incidence and Prevalence of Chronic Spontaneous Urticaria Among Adult and Pediatric Populations in the United States. Adv Ther. 2025;42(6):2808–2820. https://doi.org/10.1007/s12325-025-03172-0.

31. Weerasubpong P, Jiamton S, Phumariyapong P, Ungprasert P, Kulthanan K. Prevalence of concomitant angioedema in chronic spontaneous urticaria: A systematic review and meta-analysis. Asian Pac J Allergy Immunol. 2023;41(1):12–19. https://doi.org/10.12932/AP-151222-1515.

32. Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, Panasoff J. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59(8):869–873. https://doi.org/10.1111/j.1398-9995.2004.00473.x.

33. Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med. 2002;346(3):175–179. https://doi.org/10.1056/NEJMcp011186.

34. Maurer M, Altrichter S, Schmetzer O, Schmetzer O, Scheffel J, Church MK, Metz M. Immunoglobulin E-mediated autoimmunity. Front Immunol. 2018;9:689. https://doi.org/10.3389/fimmu.2018.00689.

35. Bracken SJ, Abraham S, MacLeod AS. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol. 2019;10:627. https://doi.org/10.3389/fimmu.2019.00627.

36. Гофман ВР, Черныш АВ, Дворянчиков ВВ. Хронический тонзиллит. М.: Техносфера; 2015. 140 с.

37. Jang JH, Yang EM, Lee Y, Ye YM, Moon J, Ryu MS, Park HS. Increased serum free IgE levels in patients with chronic spontaneous urticaria (CSU). World Allergy Organ J. 2022;15(2):100629. https://doi.org/10.1016/j.waojou.2022.100629.

38. Jang JH, Moon J, Yang EM, Ryu MS, Lee Y, Ye YM, Park HS. Detection of serum IgG autoantibodies to FcεRIα by ELISA in patients with chronic spontaneous urticaria. PLoS ONE. 2022;17(8):e0273415. https://doi.org/10.1371/journal.pone.0273415.

39. Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, Zuberbier T, Keil T. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423–432. https://doi.org/10.1111/all.14037.

40. Korkmazov MY, Kornova NV, Lengina MA, Smirnov AA, Korkmazov AM, Dubinets ID. Effective antibiotic therapy for community-acquired otorhinolaryngological respiratory infection (clinical description). Meditsinskiy Sovet. 2022;(20):73–81. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-20-73-81.

41. Khisamova AA, Gizinger OA, Kornova NV, Zyryanova KS, Korkmazov AM, Beloshangin AS. Studies of immunological and microbiological efficiency of the therapy of curcumin and methionine in the developed capsules. Russian Journal of Immunology. 2021;24(2):305–310. (In Russ.) https://doi.org/10.46235/1028-7221-1001-SOI.

42. Korneenkov AA, Ovchinnikov PA, Vyazemskaya EE, Dvoryanchikov VV, Ryazantsev SV, Yanov YK, Fanta IV. Assessment of working conditions and risks caused by the COVID-19 pandemic: results of an online survey of personnel of medical organizations. Meditsinskiy Sovet. 2023;17(7):160–169. (In Russ.) https://doi.org/10.21518/ms2023-071.

43. Ovchinnikov PA, Dvoryanchikov BB, Yanov YuK, Ryazantsev SV, Vyazemskaya EE, Fanta IV, Korneenkov AA. Study of staff awareness at ent facilities in pandemic COVID-19. Rossiiskaya Otorinolaringologiya. 2022;21(2): 51–61. (In Russ.) https://doi.org/10.18692/1810-4800-2022-2-51-61.

44. Chu CY, Al Hammadi A, Agmon-Levin N, Atakan N, Farag A, Arnaout RK et al. Clinical characteristics and management of chronic spontaneous urticaria in patient’s refractory to H1-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study. World Allergy Organ J. 2020;13(4):100117. https://doi.org/10.1016/j.waojou.2020.100117.

45. Sharma M, Bennett C, Cohen SN, Carter B. H1-antihistamines for chronic spontaneous urticaria. Cochrane Database Syst Rev. 2014;2014(11):CD006137. https://doi.org/10.1002/14651858.cd006137.pub2.

46. Williams PV. Pharmacologic Management of Chronic Urticaria in Pediatric Patients: The Gap Between Guidelines and Practice. Paediatr Drugs. 2020;22(1):21–28. https://doi.org/10.1007/s40272-019-00365-3.

47. Agache I, Rocha C, Pereira A, Song Y, Alonso-Coello P, Sola I et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy. 2021;76(1):59–70. https://doi.org/10.1111/all.14547.

48. Casale TB, Gimenez-Arnau AM, Bernstein JA, Holden M, Zuberbier T, Maurer M. Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status. Dermatol Ther. 2023;13(11):2573–2588. https://doi.org/10.1007/s13555-023-01040-9.

49. Rubini NPM, Ensina LFC, Silva EMK, Sano F, Sole D. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis. Allergol Immunopathol. 2019;47(6):515–522. https://doi.org/10.1016/j.aller.2019.05.003.

50. Seetasith A, Holden M, Hetherington J, Keal A, Salmon P, Bernstein JA, Casale TB. Real-world outcomes in patients with chronic spontaneous urticaria receiving omalizumab: insights from a clinical practice survey. Curr Med Res Opin. 2024;40(6):1059–1066. https://doi.org/10.1080/03007995.2024.2354534.

51. Casale TB, Gimenez-Arnau AM, Bernstein JA, Holden M, Zuberbier T, Maurer M. A plain language summary of a review about omalizumab for people with chronic spontaneous urticaria. Immunotherapy. 2025;17(4):239–245. https://doi.org/10.1080/1750743X.2025.2484921.

52. Ryu MS, Yang EM, Ye YM, Jang JH, Kim J, Lee SY, Park HS. Therapeutic Efficacy of YH35324 on FcεRIα-Mediated Mast Cell/Basophil Activation. Allergy Asthma Immunol Res. 2025;17(2):181–195. https://doi.org/10.4168/aair.2025.17.2.181.

53. Xiao Y, Yang W, Wang M. A comprehensive analysis on the safety of two biologics dupilumab and omalizumab. Front Med. 2024;11:1435370. https://doi.org/10.3389/fmed.2024.1435370.